In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a
boom for a variety of applications. There are significant efforts to utilize liquid biopsies in …

Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early
detection are paramount to reducing cancer-related deaths and improving patient outcomes …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …

Over the last decade, liquid biopsy has gained much attention as a powerful tool in
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …

During the past ten years, circulating tumour cells (CTCs) have received enormous attention
as new biomarkers and the subject of basic research. Although CTCs are already used in …

Extracellular vesicles (EVs) are small lipid membrane vesicles that are secreted from almost
all kinds of cells into the extracellular space. EVs are widely accepted to be involved in …